CRL on the prowl for Chinese M&As in world’s future science hub
Charles River Labs (CRL) has singled out China as an area of “disproportionate growth” in biologics R&D and says it is on the hunt for preclinical acquisitions in the region.
Archives for September 15, 2014
Trial transparency: NICE stands firm on data
The UK’s NICE says it will go over drug companies’ heads and get clinical trial data from regulators if sponsors fail to supply their results.
EMA guideline on pharmacovigilance inspections comes into effect
As the EMA has announced that the main objectives of its pharmacovigilance legislation are largely being achieved, the agency is still implementing a number of the individual modules that make up the over-arching law.
Parexel adds two clinical tech companies to partner program
CRO (contract research organization) Parexel International has allowed clinical technology companies CRF Health and Clinical Ink to join its Perceptive Partner Program.
DHL and Octapharma open cold-chain logistics centre in Germany
In a venture with plasma products manufacturer Octapharma, DHL has opened a €3.4m ($4.4m) cold-chain logistics centre in Germany for the pharma and life sciences industries.
Almac teams with Welsh academics to create P450 enzymes for industry
Almac has teamed up with Welsh Academics and industrial chemistry firm Hockley International to develop enzymes capable of making drug intermediates more quickly.
Indian drugmakers to bring cheap HCV drug Sovaldi to developing world
Gilead has granted seven Indian drugmakers licenses to produce generic versions of its $1,000 a pill drug Sovaldi to increase access to hepatitis C medicines in 91 developing countries.
Galen plans to sell “green whistle” inhalable pain drug in UK and Ireland
Almac’s subsidiary Galen has licensed UK sales and marketing rights to an emergency pain drug nicknamed the “green whistle” from Australian firm Medical Developments International (MVP).
Mannkind looks to Sanofi for secondary supply of inhalable insulin API
Mannkind says Sanofi could become a second API supplier for its recently approved inhalable insulin drug Afrezza following its commercialisation partnership last month.